ArticleWorld journal of oncology2026
Prediction of Residual Disease in Unresectable Head and Neck Squamous Cell Carcinoma After Concurrent Chemoradiotherapy.
Article in World journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Concurrent chemoradiotherapy (CCRT) for unresectable head and neck cancer (HNC) in advanced stages is associated with a high probability of residual disease (RD). Salvage surgery after completing CCRT often leads to severe complications, and palliative care is required if surgery is not feasible. The aim of this study was to develop a prediction model for RD based on pretreatment clinical features. Methods: This retrospective observational cohort study analyzed the medical records of patients with unresectable HNC who received CCRT at the Radiation Oncology Unit of Buddhachinaraj Phitsanulok Hospital, Thailand, between October 2019 and October 2025. Clinical features and laboratory results were collected before treatment. Tumor response was evaluated 8-12 weeks after completion of CCRT using computed tomography or magnetic resonance imaging scans according to the Response Evaluation Criteria in Solid Tumors. Multivariable logistic regression was used to identify predictors of RD. The model performance was evaluated for discrimination using the area under the receiver operating characteristic curve (AuROC) and for calibration using calibration plots. Internal validation was performed using the bootstrap resampling method. Decision curve analysis was also performed. Results: A total of 382 patients with HNC were included. After the completion of CCRT, 180 patients (47.1%) presented with RD. The final model retained primary tumor site (hypopharynx (odds ratio (OR): 3.56; 95% confidence interval (CI): 1.10-11.40) and oral cavity (OR: 3.77; 95% CI: 0.95-14.90)), maximum tumor diameter (OR: 3.37; 95% CI: 2.59-4.39), time to initiation of radiotherapy (OR: 1.01; 95% CI: 1.00-1.02), body mass index (OR: 0.97; 95% CI: 0.88-1.06), neutrophil-to-lymphocyte ratio (OR: 1.02; 95% CI: 0.94-1.10), and hemoglobin level (OR: 0.94; 95% CI: 0.79-1.11). The model demonstrated excellent discrimination, with an AuROC of 0.929 (95% CI: 0.903-0.954). At an RD probability cutoff of ≥ 47.1%, the model yielded a positive predictive value of 81.2% (95% CI: 75.1-86.4) and a negative predictive value of 89.2% (95% CI: 83.8-93.3). Conclusions: This clinical feature-based prediction model accurately predicted the probability of RD in patients with unresectable HNC. Physicians can utilize this model for pre-CCRT treatment planning to identify high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.